Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ARS1620 |
| Trade Name | |
| Synonyms | ARS-1620 |
| Drug Descriptions |
ARS1620 is a covalent inhibitor of KRAS G12C, which may inhibit ERK activation and proliferation in tumor cells harboring KRAS G12C, particularly in combination with other targeted agents (PMID: 30327306, PMID: 29373830, PMID: 31776128). |
| DrugClasses | KRAS G12C inhibitor 36 |
| CAS Registry Number | 1698055-85-4 |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ARS1620 | ARS1620 | 0 | 0 |
| ARS1620 + Everolimus | ARS1620 Everolimus | 0 | 0 |
| ARS1620 + Everolimus + Linsitinib | ARS1620 Everolimus Linsitinib | 0 | 0 |
| ARS1620 + Gefitinib | ARS1620 Gefitinib | 0 | 0 |
| ARS1620 + Linsitinib | ARS1620 Linsitinib | 0 | 0 |
| ARS1620 + Osimertinib | ARS1620 Osimertinib | 0 | 0 |
| ARS1620 + Pictilisib | ARS1620 Pictilisib | 0 | 0 |